FDA sets approval path for Prosensa muscle disorder drug

(Reuters) – Prosensa Holding NV said the U.S. Food and Drug Administration had outlined an accelerated regulatory approval path for its most advanced drug, aimed at treating a muscle disorder. The Netherlands-based company said on Tuesday it planned to conduct two more studies, and…

Source:FDA sets approval path for Prosensa muscle disorder drug